Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-01-09 00:00:00 ET · period of report 2026-01-07 · accession 0000875320-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | 2026-01-07 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $474.99 | -4,500 | 42.3K | -10% | -$2.14M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-07 | S | D | 4,500 | $474.99 | 42,293 | D | — | — |